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Abstract
Background: HOX cofactors enhance HOX binding affinities and specificities and increase HOX's
unique functional activities. The expression and the regulation of HOX cofactors in human ovaries
are unknown.
Methods: In this study, the expression of HOX cofactors, PBX1, PBX2, and MEIS1/2, were
examined by using RT-PCR, immunofluorescence in cultured immortalized human granulosa
(SVOG) cells. The distribution of these HOX cofactors in human ovaries was examined by
immunohistochemistry. The effects of growth differentiation factor-9 (GDF-9) and follicle-
stimulating hormone (FSH) on PBX2 in SVOG cells were investigated by western blot analysis.
Binding activities of HOXA7 and PBX2 to the specific sequences in granulosa cells were
determined by electrophoretic mobility shift assay (EMSA).
Results and conclusion: In SVOG cells, PBX1, PBX2 and MEIS1/2 were expressed during cell
culture. In normal human ovaries, PBX1 and MEIS1/2 were expressed in granulosa cells at
essentially all stages of follicular development. These cofactors were expressed in the nuclei of the
granulosa cells from the primordial to the secondary follicles, whereas beyond multilayered follicles
was observed in the cytoplasm. The co-expression of PBX1 and MEIS1/2 in granulosa cells in
normal human ovaries suggested that MEIS1/2 might control PBX1 sublocalization, as seen in other
systems. PBX2 was not expressed or weakly expressed in the primordial follicles. From the primary
follicles to the preovulatory follicles, PBX2 expression was inconsistent and the expression was
found in the granulosa cell nuclei. The PBX2 expression pattern is similar to HOXA7 expression
in ovarian follicular development. Furthermore, FSH down-regulated, GDF-9 did not change PBX2
expression, but co-treatment of the granulosa cells with FSH and GDF-9 up-regulated PBX2
expression. These results implicated a role for PBX2 expression in the steroidogenic activities of
granulosa cells in humans. Moreover, PBX2 and HOXA7 bound together to the Pbx sequence, but
not to the EMX2 promoter sequence, in SVOG cells. Our findings indicate that HOX cofactors
expression in normal human ovary is temporally and spatially specific and regulated by FSH and
GDF-9 in granulosa cells. HOX proteins may use different HOX cofactors, depending on DNA
sequences that are specific to the granulosa cells.
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Background
Transcription factors play important roles in oogenesis
and folliculogenesis [1,2]. Numerous studies have
emphasized the importance of ovarian-specific transcrip-
tion factor genes during ovarian follicular development.
However, non-ovarian-specific genes are also expressed
during ovarian follicular development, and their potential
functions in folliculogenesis, such as steroidogenesis, are
not known [3-5].
Homeobox genes are transcription factors that encode
homeodomain-containing DNA-binding proteins that
specify the anterior-posterior orientation of a variety of
organs during embryonic development and regulate dif-
ferentiation in the adult tissues. The homeodomain is
highly conserved in Hox proteins. Hox share similar DNA
binding specificities in vitro. In vivo, Hox cofactors
enhance their target DNA binding affinities and specifici-
ties [6,7]. Homeobox domains in Hox cofactors contain a
three-amino acid loop extension (TALE), which can be
classified into two groups: Pbx and Meis/Prep. Pbx binds
to groups 1 to 10 (out of 13 paralogous Hox groups) and
Meis proteins bind to groups 9–13. However, recent stud-
ies have shown that Meis1 also can bind to anterior Hox
proteins [8] in vitro. In addition, Meis proteins interact
directly with Pbx and participate in the DNA bound Hox
complex and regulate the sublocalization of Pbx [7].
Pbx has four subclasses: Pbx1–4. Pbx1 was first identified
in acute pre-B-cell leukemias [9]. The Pbx2, Pbx3, Pbx4
genes were subsequently identified [10,11]. In the female
reproductive system, Pbx1 is expressed in the coelomic
epithelium [12]. Pbx1 encodes two spliced variants Pbx1a
and Pbx1b. Pbx1a is not expressed in the developing
female reproductive systems, whereas Pbx1b is expressed
in the Müllerian ducts at embryonic day 14.5 (E14.5)
[13]. Pbx1-deficient mice die at E15.5-E16.5, with axial
skeletal malformations and abnormalities of multiple
organs [14], including improper differentiation of the
gonads and an absence of Müllerian ducts [12]. In devel-
oping embryos, at E14.5, weak Pbx3 expression was
observed throughout the ovary [15]. Pbx3-deficient mice
survive to term but die within a few hours of birth [16],
and there is no description about reproductive system
anomalies thus far. The expression patterns of Pbx1 and
Pbx3 are overlapped during embryonic development, and
they could have redundant functions. In contrast, Pbx2 is
not crucial for development, which implies possible com-
pensation by other Pbx isoforms [17].
Three Meis isoforms (Meis1, Meis2 and Meis 3) are all
expressed in newborn and 10-week old mice in the ovary
[8]. Meis1 null mice die at E14.5 and are deficient in nor-
mal capillaries, megakaryotes and eyes [18,19], but there
was no description about the reproductive system in these
reports. Immunohistochemical studies have shown that,
in newborn female reproductive systems, Meis1 is
expressed throughout the ovary, uterus, cervix and vagina
[8]. Meis2 is not expressed in the gonad primodium at
E9.5–11.5, but, in adult mice, the Meis2c and Meis2d iso-
forms are expressed [20]. MEIS1 and MEIS2 are expressed
in the nuclei of normal adult human ovarian surface epi-
thelium; however, their functions in the ovary have not
been elucidated [21].
In this study, we examined the immunohistochemical dis-
tribution of HOX cofactors in normal human premeno-
pausal ovaries. We also examined PBX1, PBX2 and
MEIS1/2 expression in immortalized granulosa cells in
vitro. Furthermore, because PBX2 expression was
observed to be similar to HOXA7 as seen in our previous
study [3], we focused on PBX2 and investigated the regu-
lation of PBX2 by FSH and GDF-9 treatment and on the
DNA binding activities of PBX2 and HOXA7 in granulosa
cells.
Methods
Materials
The antibodies for PBX1 (sc-889), PBX2 (sc-890), MEIS1/
2 (sc-10599), MEIS1/2 blocking peptide (sc-10599p) and
actin (C-11) were purchased from Santa Cruz Biotechnol-
ogy Ltd. (Santa Cruz, CA). The epitopes of the MEIS1/2
antibody was designed for MEIS1, however, has 94% sim-
ilarities with MEIS2. Human recombinant FSH was pur-
chased from Dr. A.F. Parlow (National Hormone and
Pituitary Program, CA). GDF-9 was kindly provided by
Dr. A. J.W. Hsueh (Stanford University, CA).
Tissues
The use of human tissues and cells was approved by the
committee for ethical review of research involving human
subjects of the University of British Columbia. Paraffin
sections were obtained from grossly and histologically
normal ovaries of 7 premenopausal women, collected by
the Department of Pathology (UBC) with patient consent.
Premenopausal status was confirmed by the presence of
follicles or corpora lutea. Carcinoma was excluded in all
of the ovarian samples used in this study by histopatho-
logical assessment.
Cell culture
SV40 Tag-immortalized human granulosa cells (SVOG)
were generated, as described previously [22], by transfec-
tion of the SV40 early genes Tag/tag into human granulosa
cells obtained from IVF procedures. SVOG cells were
maintained in 199/MCDB 105/10% FBS with 0.4 μg/ml
hydrocortisone (BD Biosciences Clontech, Mountain
View, CA). A cervical cancer cell line, Hela, and an eryth-
roleukemic cell line, K562, were purchased from the
American Type Culture Collection (ATCC). Ishikawa cellsReproductive Biology and Endocrinology 2008, 6:49 http://www.rbej.com/content/6/1/49
Page 3 of 9
(page number not for citation purposes)
were provided by Dr. Taylor (Yale University). Hela cells
were maintained in DMEM (Invitrogen, Burlington, ON)
supplemented with 10% FBS (Hyclone Laboratories Ltd.,
Logan, UT). K562 cells were maintained in RPMI 1640
medium (Invitrogen) with 15% FBS. Ishikawa cells were
maintained in DMEM/F-12 with 5% FBS. All cells were
grown in a 5% CO2/air atmosphere, and Hela, Ishikawa
and SVOG cells were passaged using 0.06% trypsin/0.01%
EDTA in Ca2+-, Mg2+-free Hanks' BSS.
RT-PCR
Total RNA was extracted from cultured cells using the
RNeasy kit (Qiagen Inc., Mississauga, ON) according to
the manufacturer's procedure. Complementary DNA was
transcribed from 1.5 μg total RNA using a First Strand
cDNA synthesis kit (Amersham, Oakville, Ont., Canada)
and used as a template for polymerase chain reaction
(PCR). All PCR primers span introns in order to detect
specific mRNA sequences. The forward and reverse prim-
ers used were as follows: PBX1 (NM_002585): 5'-
CCACGTGATGAATCTCCTGCGAGAG-3' and 5'-TCACT-
GTATCCTCCTGTCTGGCTGA-3', PBX2 (NM_002586):
5'-CTGGTTTGGCAACAAGAGGATTCGC-3' and 5'-
TGGAGGTATCAGAGTGAACACTCCC-3' and MEIS1
(BC043503): 5'-AAGGTGATGGCTTGGACAA-3' and 5'-
GGCTGCACTATTCTTCTCCG-3'. The expected size of
PCR products using these sets of primers are 627 bp for
PBX1a, 414 bp for PBX1b, 411 bp for PBX2, and 259 bp
for MEIS1. The amplification reaction was carried out in
the linear range of the logarithmic phase unless otherwise
specified. Each cycle consisted of denaturation at 95°C for
30 s, primer annealing at 55°C for 30 s, extension at 72°C
for 60 s and a final extension at 72°C for 5 min in a DNA
thermal cycler (Mini cyclerTM, PTC-100 TM, MJ-Research,
Bio-Rad). PCR products were verified by sequence analy-
sis.
Western blot analysis
Cells were washed with ice-cold PBS and lysed by cold
lysis buffer (1% Triton X-100, 0.5% sodium deoxycholate,
0.1% SDS in PBS, pH 7.4), including freshly added pro-
tease inhibitor (Sigma, St. Lois, MO). The extracts were
placed on ice for 10 min, vortexed briefly and centrifuged
for 15 min at 4°C to remove cell debris. The total protein
concentration was determined using a Bradford assay
(Bio-Rad Laboratories, Mississauga, ON). The samples
were boiled for 10 min before running the gels. SDS poly-
acrylamide gel electrophoresis (SDS-PAGE) was per-
formed using a 10% separating gel. Twenty-five to 30 μg
of protein was then electrotransferred to a nitrocellulose
membrane (Bio-Rad Laboratories). The membrane was
blocked with 5% skim milk in PBS. PBX2 and actin were
detected by primary antibodies in 5% skim milk/TBS for
1 hr at 25°C. Subsequently, the signals were detected with
secondary antibodies conjugated with horse radish perox-
idase and visualized by ECL (Pierce, Rockford, IL).
Immunofluorescence
For PBX1 and MEIS1/2, cells were grown on glass cover-
slips, fixed in freshly prepared 4% paraformaldehyde in
PBS for 10 min at 4°C, and permeabilized with 0.1% Tri-
ton X-100 in PBS for 10 min at 25°C. For PBX2, cells on
the coverslips were fixed in cold methanol and postfixed
in cold methanol/acetone (1:1). The cells were incubated
with primary antibodies, anti-PBX1 (1:20), anti-PBX2
(1:50) and anti-MEIS1/2 antibody (1:50). The binding of
primary antibodies was followed by goat anti-mouse anti-
body (Alexa Fluor 594, Molecular Probes, Eugene, Ore-
gon) or rabbit anti-goat antibody (Alexa Fluor 488,
Molecular Probes). Control experiments were done in the
absence of primary antibodies and verified their no or lit-
tle background. For Hoechst staining, after incubation of
the secondary antibodies, cells were incubated for 1 min
with 5 μg/ml Hoechst 33258.
Immunohistochemistry
Ishikawa, Hela and K562 cell pellets were solidified by
collagen gel, fixed in 4% paraformaldehyde, and embed-
ded in paraffin. Sections of these cells and of the ovaries
were deparaffinized, rehydrated, and submitted to antigen
retrieval by a steamer for 30 min in 10 mM citric buffer
(PBX2) or Target Retrieval Solution (DAKO, Mississauga,
ON; PBX1 and MEIS1/2). Endogenous peroxide was
diminished with 3% H2O2 for 30 min. Nonspecific bind-
ing was blocked with 3% BSA in PBS (PBX2) or Protein
Block (DAKO; PBX1 and MEIS1/2) for 30 min, followed
by incubation with primary antibodies overnight at 4°C.
The dilution of the primary antibodies was the same as
that described for the immunofluorescence. Samples
without primary antibodies were used as a negative con-
trol. There was no or little background without primary
antibodies. The sections were then incubated with Bioti-
nylated link universal (DAKO) for 15 min and streptavi-
din (DAKO) for 25 min at 25°C. Slides were developed in
diaminobenzine (DAKO) or in NovaRED substrate (Vec-
tor Laboratories, Inc., Burlington, ON) and counter-
stained with hematoxylin.
Electrophoretic Mobility-Shift Assay (EMSA)
Nuclear extracts were prepared with a nuclear extract kit
(Panomics, Inc., Redwood City, CA) according to the
manufacturer's instructions. DNA-binding reactions were
performed with equal amounts of nuclear proteins (10
μg) and 32P-labeled probes at 25°C for 10 min. The fol-
lowing synthetic double-strand oligonucleotide probes
were used: Pbx, 5'-CGAATTGATTGATGCACTAATTGGAG-
3', and EMX2, 5'-AGGAAGCTGTTTATGTGATCCCCG-3',
which have been previously shown to contain the consen-
sus recognition sequences for the HOX-Pbx complexesReproductive Biology and Endocrinology 2008, 6:49 http://www.rbej.com/content/6/1/49
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[23,24]. For cold competition assays, a 100-fold excess of
unradiolabeled oligonucleotides was added to the reac-
tions prior to the 32P-labeled probes. Anti-HOXA7 and
anti-PBX2 antibodies used in the supershift experiments
were added to the nuclear extract at 25°C for 30 min
before the addition of labeled probe. Protein-DNA com-
plexes were resolved in 5% polyacrylamide gel containing
1× TBE (Tris-borate-EDTA: 0.09 M Tris-borate and 2 mM
EDTA, pH 8.0). Before loading of the samples, the gel was
pre-run for 90 min at 100 V at 4°C. Electrophoresis was
carried out at 120 V at 4°C. The gel was then dried under
vacuum and exposed to Kodak X-OMAT AR film (Kodak,
Rochester, NY).
Results
Expression of HOX cofactors in immortalized granulosa 
cells
Recent studies have identified a number of HOX genes in
the oocytes, and we have previously shown the distribu-
tion of HOXA7 in ovarian follicular development [3]. To
examine the expression of HOX cofactors in normal
human ovary, we focused on PBX1, PBX2 and MEIS1/2. In
addition, to determine the expression of HOX cofactors in
human granulosa cells, we performed RT-PCR following
the culture of SVOG cells. Figure 1A showed that PBX1,
PBX2 and MEIS1 are transcribed in proliferating SVOG
cells. Two transcripts corresponding to PBX1a and PBX1b
were detected, and PBX1b, which lacks the C-terminal
domain in PBX1a, was the more predominant form in
SVOG cells (Figure 1A). The specificities of the HOX
cofactors antibodies were confirmed by using paraffin-
embedded Ishikawa, Hela and K562 cells (data not
shown). By immunofluorescence, PBX1 was observed to
be expressed both in the nuclei and in the cytoplasm,
which is consistent with the results reported in Hela or
Ishikawa cells (Figure 1B) [25]. In SVOG cells, PBX2 and
MEIS1/2 were expressed in the nuclei.
Immunohistochemistry
The distribution of PBX1, PBX2 and MEIS1/2 was exam-
ined by immunohistochemistry on paraffin sections of
premenopausal ovaries. Five ovaries were used for PBX1
and 6 ovaries were used for MEIS1/2 and PBX2. Immuno-
histochemical specificity of the anti-MEIS1/2 antibody
was confirmed by using MEIS1/2 blocking peptide (data
not shown). As shown in Figure 2, oocyte nuclei were neg-
ative, and oocyte cytoplasms were weakly positive, at all
stages for PBX1, PBX2 and MEIS1/2. PBX1 staining was
observed in the nuclei of granulosa cells from primordial
to secondary follicles. In 50% of primordial follicles, gran-
ulosa cells were partially positive (Figure 2A; Table 1). In
contrast, in primary and secondary follicles, almost all
granulosa cells were completely positive (Figure 2B, C;
Table 1). In multilayered and Graffian follicles, similar to
HOXA7, PBX1 had mainly translocated to the cytoplasm
Expression of HOX cofactors in immortalized human granu- losa (SVOG) cells in culture Figure 1
Expression of HOX cofactors in immortalized human 
granulosa (SVOG) cells in culture. (a) mRNA levels of 
PBX1, PBX2 and MEIS1. control, no cDNA. (b). Levels of 
PBX1, PBX2 and MEIS1/2 as shown by immunofluorescence 
microscopy. The staining of nuclei with Hoechst is shown in 
the right column. (scale bar = 20 μm).Reproductive Biology and Endocrinology 2008, 6:49 http://www.rbej.com/content/6/1/49
Page 5 of 9
(page number not for citation purposes)
(Figure 2J). The theca interna were positive, and the theca
externa were weakly positive (Figure 2J). In the theca, the
expression was also in the cytoplasm. MEIS1/2 expression
was quite similar to PBX1 expression (Figure 2G, H, I, L).
In primordial follicles, the percentage of MEIS1/2 nega-
tive granulosa cells was more compared to PBX1 (Table
1). Other differences between PBX1 and MEIS1/2 stain-
ings were that the theca interna were positive but showed
both nuclear and cytoplasmic staining for MEIS1/2 (Fig-
ure 2L).
PBX2 expression in normal human ovaries was com-
pletely different from PBX1 and MEIS1/2 expression.
Interestingly, the expression pattern was similar to
HOXA7 expression as we previously observed [3]. Granu-
losa cells in primordial follicles were negative or weakly
positive (Figure 2D; Table 1). From the primary to Graf-
fian follicles, the intensity of PBX2 expression in granu-
losa cells became higher when compared to the
primordial follicles and the expression pattern was mixed,
i.e., negative and positive (Figure 2E, F, K; Table 1). The
cells of the theca interna were positive, and the cells of the
theca externa were negative, which was again similar to
HOXA7 expression. PBX2 expression in the theca interna
was in the nuclei.
Effects of FSH and GDF-9 on PBX2 expression
Since PBX2 expression in human normal ovaries was
observed to be similar to HOXA7 expression, we focused
on the regulation of PBX2 expression. In our previous
study, HOXA7 is regulated by GDF-9 [3]. In the present
study, to investigate whether PBX2 expression is regulated
in SVOG cells, the cells were treated with FSH (100 ng/ml)
and/or GDF-9 (50 or 100 ng/ml). Our results showed that
PBX2 expression was down-regulated by treatment with
FSH, but not changed by GDF-9 alone (Figure 3). Interest-
ingly, concomitant treatment with FSH and GDF-9 up-
regulated the expression of PBX2 when compared to the
control (Figure 3).
HOXA7 and PBX2 bind to the Pbx consensus sequence as
a heterodimer The HOX-PBX heterodimeric complex can
bind to the Pbx and EMX2 consensus sequences
[23,24,26]. Therefore, we investigated the possibility that
HOXA7 and PBX2 may cooperatively bind to these two
DNA sequences by EMSA. PBX and EMX2 binding activi-
ties were observed in SVOG cells (Lane 3, Figure 4A, B).
The specificity of binding to the respective probes was
determined by using a 100-fold molar excess of unlabeled
oligonucleotide as a competitor, which indicated that the
bound complexes resulted from sequence specific DNA-
protein interactions (Lane 1, Figure 4A, B).
To examine whether HOXA7 and PBX2 were present in
the complexes, supershift analysis was performed using
antibodies directed against the two proteins. Strikingly,
the addition of anti-HOXA7 and/or anti-PBX2 antibodies
caused supershifts of the complexes bound to the Pbx
sequence, resulting in two bands with apparently higher
molecular weights (Lanes 4, 5 and 6, Figure 4A). In con-
trast, whereas addition of the anti-HOXA7 antibody pro-
duced a characteristic shift in the complexes formed with
the EMX2 probe, the PBX2 antibody alone did not result
in a marked supershift (Lanes 4, 5, Figure 4B). These data
revealed a differential recruitment of PBX2 to the Pbx and
EMX2 consensus sequences. HOXA7 may bind to Pbx as a
heterodimer with PBX2 and to EMX2 with other cofac-
tor(s).
Discussion
In this study, we demonstrated for the first time the
expression of HOX cofactors in normal human ovaries
and, particularly, in human granulosa cells. During cell
culture, PBX1 was observed in the nuclei and the cyto-
Table 1: Expression of HOX cofactors in granulosa cells during follicular development
negative positive Strongly positive total
PBX1
primordial 1 (6%) 9 (50%) 8 (44%) 18
primary 1 (2.5%) 1 (2.5%) 41 (95%) 43
secondary 0 (0%) 0 (0%) 2 (100%) 2
multi, Graffian 4 (100%) 0 (0%) 0 (0%) 4
PBX2
primordial 4 (21%) 15 (79%) 0 (0%) 19
primary 3 (10%) 20 (67%) 7 (23%) 30
secondary, multi, Graffian 0 (0%) 5 (83%) 1 (17%) 6
MEIS1/2
primordial 8 (36%) 12 (55%) 2 (9%) 22
primary 6 (18%) 27 (79%) 1 (3%) 34
secondary 0 (0%) 0 (0%) 4 (100%) 4
multi, Graffian 5 (100%) 0 (0%) 0 (0%) 5Reproductive Biology and Endocrinology 2008, 6:49 http://www.rbej.com/content/6/1/49
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Immunohistochemical staining for PBX1, PBX2 and MEIS1/2 in human ovaries Figure 2
Immunohistochemical staining for PBX1, PBX2 and MEIS1/2 in human ovaries. (A, B, C, J) PBX1, (D, E, F, K) PBX2 
and (G, H, I, L) MEIS1/2. (A, D, G): primordial follicles. (B, E, H): primary follicles. (C, F, I): secondary follicles. (J, K, L): preovu-
latory follicles. Figure 2E contains both primordial and primary follicles, and Figure 2I contains both primordial and secondary 
follicles (scale bars: A,B,D,E,G,H = 9 μm, C,F,I = 40 μm, J,K,L = 350 μm).Reproductive Biology and Endocrinology 2008, 6:49 http://www.rbej.com/content/6/1/49
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plasm, whereas PBX2 and MEIS1/2 were observed only in
the nuclei in proliferating SVOG cells. In normal human
ovaries in situ, PBX1 and MEIS1/2 were expressed in the
nuclei in granulosa cells from primordial to secondary fol-
licles. In Graffian follicles, the expression of both PBX1
and MEIS1/2 was translocated from the nuclei to the cyto-
plasm of the granulosa cells. There is a correlation
between PBX1 expression and the cell cycle [25]. PBX1
expression in the nucleus from the primordial to the sec-
ondary follicles might show that granulosa cells are at the
G2/M phase, while the cytoplasmic PBX1 expression in
preovulatory follicles might indicate that these granulosa
cells are not dividing. Compared to ovaries in mice, PBX1
expression in human ovaries was more evident, and PBX2
expression was similar [5]. The discrepancies might be
due to species differences. MEIS1 and MEIS2 control PBX1
nuclear localization where the PBX1 gene is functional
[27], whereas recent studies have shown that PBX1
nuclear localization does not require both MEIS proteins
[25]. In our in vitro experiments, MEIS1/2 was consist-
ently observed in the nuclei of SVOG cells, while PBX1
was expressed both in the nuclei and in the cytoplasm. In
contrast, during ovarian follicular development, PBX1
and MEIS1/2 were expressed in the same pattern in situ,
which indicates that MEIS1/2 might control PBX1 nuclear
localization in vivo. The explanation underlying the sub-
cellular localization differences in PBX1 and MEIS1/2 in
vitro and in vivo is not known.
Similar to HOXA7, PBX2 expression was negative in pri-
mordial follicles but positive from the stage of primary
follicles. Furthermore, the mixed negative and positive
expression pattern was also similar to HOXA7. One differ-
ence is in preovulatory follicles; PBX2 was expressed in the
nuclei, whereas HOXA7 is expressed mainly in the cyto-
plasm [3]. Thus far, the role of different sublocalization of
HOXA7 is not known. These results support the notion
that HOXA7 and PBX2 might act together in granulosa
cells, especially when they are co-expressed in the nuclei.
By FSH and/or GDF-9 treatment, PBX2 expression in gran-
ulosa cells might be reversely related to steroidogenic
activities. The immortalized granulosa (SVOG) cells used
in this study are steroidogenic, as demonstrated by
increased progesterone production following treatment
with cAMP or pregnenolone in our earlier report [22]. It is
well known that FSH and cAMP up-regulates StAR expres-
sion and stimulates steroidogenesis in human granulosa
cells [28]. In the present study, treatment of SVOG cells
with FSH alone decreased PBX2 expression. GDF-9 on its
own did not change StAR [28], and, in our study, GDF-9
had no or weak inhibitory effects on progesterone produc-
tion in SVOG cells (data not shown), and it did not
change PBX2 expression. FSH or cAMP-stimulated proges-
terone production, which is mediated through StAR, was
potently inhibited by GDF-9 co-application in human
granulosa cells [28]. In the present study, PBX2 expression
was increased by the co-application of FSH and GDF-9.
Hence, PBX2 expression might be inversely related to ster-
oidogenesis in human granulosa cells. This notion is in
accordance with our demonstration that PBX2 was
expressed in the granulosa and theca interna cells that
produce estrogen and androgen, respectively, but not in
theca externa that lack steroidogenic activity.
To validate the PBX2 and HOXA7 protein-protein interac-
tion in SVOG cells, we examined their binding to two tar-
get sequences: PBX and EMX2. Previous studies showed
that complexes of Pbx1 and HOX1–4 display optimal
binding to the target sequence 5'-CGAATTGATTGAT-
GCACTAATTGGAG-3' [23] and Pbx2 is also known to
bind to this sequence [26]. TGAT is a Pbx binding site and
TNAT is a HOX site. The TAAT, the HOX binding site
which was used in this study, is accepted to bind the mid-
dle paralog groups 3–8 [29]. In addition, PBX2 and
HOXA10 interactions with EMX2 were demonstrated in
endometrial cancer cell lines [24]. EMX2 is expressed in
the epithelial components of the urogenital system during
development, and, as shown by its knockout studies, this
gene is essential for the development of the female repro-
ductive system [30]. In this study, HOXA7 and PBX2 com-
Effects of FSH and GDF-9 on PBX2 in SVOG cells Figure 3
Effects of FSH and GDF-9 on PBX2 in SVOG cells. 
The cells were treated with FSH (100 ng/ml) or/and GDF-9 
(50 or 100 mg/ml). For co-treatment, cells were pre-treated 
with FSH for 4 hr and then treated with GDF-9 for 24 hr.Reproductive Biology and Endocrinology 2008, 6:49 http://www.rbej.com/content/6/1/49
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plexes bound to the Pbx sequence, but not to the EMX2
sequence. The results indicate that a HOXA7 and PBX2
interaction occurs in granulosa cells. EMX2 can be a target
of HOXA7, but it did not bind to PBX2 in granulosa cells.
These results suggest that HOXA7 and PBX2 can make
dimers in granulosa cells. However, when HOXA7 binds
to the EMX2 promoter in granulosa cells, different cofac-
tors might be used to enhance the HOXA7 binding specif-
icity and strength.
HOXA7 and PBX2 bind as a heterodimer to the Pbx sequence, but not to EMX2 Figure 4
HOXA7 and PBX2 bind as a heterodimer to the Pbx sequence, but not to EMX2. EMSA analysis was performed 
with 32P-labeled oligonucleotides containing the (A) Pbx consensus sequence and (B) EMX2 consensus sequence. Supershift 
assays were also performed with antibodies to HOXA7 and PBX2. Lanes are designated as follows: lane 1, negative control 
using excess unlabeled cold probe (100×) with nuclear extract; lane 2, 32P-labeled probe without nuclear extract, showing the 
migration of free probe in absence of nuclear extract; lane 3, 32P-labeled probe with nuclear extract; lane 4, supershift reaction 
with 32P-labeled probe, nuclear extract and anti-PBX2 antibody; lane 5, supershift reaction with 32P-labeled probe, nuclear 
extract and anti-HOXA7 antibody; lane 6, supershift reaction with 32P-labeled probe, nuclear extract, anti-Pbx2 and anti-
HOXA7 antibodies; lane 7, 32P-labeled probe without nuclear extract but with anti-PBX2 and anti-HOXA7 antibodies. Abbre-
viation: n.s., non-specific complex.
+ + + - - - -
+ + - + - - -
- + + + + - +
+ + + + + + +
- - - - - - +
+ + + - - - -
+ + - + - - -
- + + + + - +
+ + + + + + +
- - - - - - + Unlabeled probe
32P-labeled probe
Nuclear extract
Anti-Pbx2 Ab
Anti-HOXA7 Ab
Unlabeled probe
32P-labeled probe
Nuclear extract
Anti-Pbx2 Ab
Anti-HOXA7 Ab
A. Pbx probe B. EMX2 probe
1   2   3   4   5   6   7 
Free probe Free probe
n.s.
n.s.
complexes
n.s.
n.s.
complexes
supershifts
supershift
1   2   3   4   5   6   7 Reproductive Biology and Endocrinology 2008, 6:49 http://www.rbej.com/content/6/1/49
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Conclusion
In summary, this study demonstrated, for the first time,
the expression and regulation of HOX cofactors in normal
human ovaries. The results indicate that PBX1 and MEIS1/
2 might act together and that PBX2 and HOXA7 act
together at specific promoter regions in human granulosa
cells. It appears that PBX2 expression is closely related to
steroidogenic activities in granulosa cells and that it plays
a role in ovarian follicular development.
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